Panbela Therapeutics (PBLA) Stock Price, News & Analysis

Company Overview

Panbela Therapeutics, Inc. (NASDAQ: PBLA) is a clinical‐stage biotechnology company focused on developing first‐in‐class therapies that modulate polyamine metabolism to treat aggressive cancers. The company’s lead investigational compound, SBP-101, is a proprietary stabilized spermine analogue designed to induce tumor cell apoptosis by dysregulating polyamine levels. Panbela has centered its pipeline largely on SBP-101 in combination with standard‐of‐care regimens for high‐mortality indications such as metastatic pancreatic adenocarcinoma and high‐risk myelodysplastic syndromes (HR-MDS).

In its pancreatic cancer program, Panbela is evaluating SBP-101 alongside gemcitabine and nab-paclitaxel in a Phase 1b/2 study, with interim data having been presented at major oncology conferences. A separate Phase 1/2 study is assessing SBP-101 plus azacitidine in patients with HR-MDS. The company continues to explore additional solid‐tumor and hematologic indications where polyamine pathway disruption may offer therapeutic benefit.

Headquartered in Minneapolis, Minnesota, Panbela Therapeutics operates as a public company listed on the Nasdaq Global Market. The organization emerged from a series of technology transfers aimed at commercializing novel polyamine modulators. Panbela’s executive leadership is led by President and Chief Executive Officer Michael B. MacDougall, M.D., with Christine Cannella serving as Chief Financial Officer.

Panbela conducts its clinical trials primarily in the United States and is actively pursuing global regulatory strategies. The company collaborates with leading academic cancer centers to advance its development programs and prepare for potential regulatory filings in both North American and international markets.

Key Stats

• Today's Range: $0.0110 to $0.0110
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.31
• Volume: 460 shs
• Average Volume: 844 shs
• Market Capitalization: $53.41 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Panbela Therapeutics Stock Analysis - MarketRank™

Panbela Therapeutics scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Panbela Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Panbela Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Panbela Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Panbela Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Panbela Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Panbela Therapeutics does not currently pay a dividend.

Dividend Growth

Panbela Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Panbela Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Panbela Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.01% of the stock of Panbela Therapeutics is held by insiders.

Percentage Held by Institutions

4.37% of the stock of Panbela Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/10/2023
• Today: 5/30/2026
• Next Earnings (Estimated): 8/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:PBLA
• CIK: 1029125
• Web: www.panbela.com
• Phone: (952) 479-1196
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 4,855,000
• Free Float: 4,855,000
• Market Cap: $53.41 thousand
• Optionable: Not Optionable
• Beta: 43.36